category
Nature Communications
date
Mar 25, 2026
slug
status
Published
summary
开发了基于结构工程的组蛋白H3竞争性LSD1抑制剂TAS1440,通过提高特异性并减少脱靶效应,在SCLC细胞中实现转录调控和表观遗传重编程,克服现有LSD1抑制剂的局限性。
tags
核酸蛋白工具酶
type
Post

📄 原文题目

LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC

🔗 原文链接

💡 AI 核心解读

开发了基于结构工程的组蛋白H3竞争性LSD1抑制剂TAS1440,通过提高特异性并减少脱靶效应,在SCLC细胞中实现转录调控和表观遗传重编程,克服现有LSD1抑制剂的局限性。

📝 英文原版摘要

<p>Nature Communications, Published online: 25 March 2026; <a href="https://www.nature.com/articles/s41467-026-70984-1">doi:10.1038/s41467-026-70984-1</a></p>Existing inhibitors for lysine-specific histone demethylase 1A (LSD1), a key driver for small cell lung cancer (SCLC) carcinogenesis, have notable limitations. Here, the authors employ structure-based engineering to develop a histone H3-competitive LSD1 inhibitor to enhance specificity and reduce off-target effects in SCLC cells through transcriptional regulation and epigenetic reprogramming.
界面阴影代谢Strand-seq与个性化基因组学的未来
Loading...